PGIM Jennison Health Sciences Fund's Q2 2024 investor letter discusses its performance, highlighting Apellis Pharmaceuticals, Inc. (APLS) as a key stock. Despite a decline, the fund sees potential in AI stocks for higher returns.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing